Enanta Pharmaceuticals, Inc. (ENTA) Given Average Recommendation of “Buy” by Brokerages

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has been given a consensus rating of “Buy” by the seven ratings firms that are presently covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $45.25.

A number of equities research analysts have weighed in on the stock. J P Morgan Chase & Co reissued an “overweight” rating and set a $38.00 target price (up from $32.00) on shares of Enanta Pharmaceuticals in a report on Wednesday, August 9th. Robert W. Baird upped their price objective on shares of Enanta Pharmaceuticals from $27.00 to $36.00 and gave the company a “neutral” rating in a research note on Tuesday, August 8th. Royal Bank Of Canada started coverage on shares of Enanta Pharmaceuticals in a research note on Thursday, September 14th. They issued an “outperform” rating on the stock. Zacks Investment Research lowered shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. Finally, JMP Securities upped their price objective on shares of Enanta Pharmaceuticals from $40.00 to $53.00 in a research note on Wednesday, October 4th.

Several institutional investors have recently added to or reduced their stakes in ENTA. Texas Permanent School Fund boosted its position in Enanta Pharmaceuticals by 0.8% during the second quarter. Texas Permanent School Fund now owns 10,146 shares of the biotechnology company’s stock worth $365,000 after purchasing an additional 85 shares during the period. Municipal Employees Retirement System of Michigan boosted its position in Enanta Pharmaceuticals by 3.5% during the second quarter. Municipal Employees Retirement System of Michigan now owns 3,280 shares of the biotechnology company’s stock worth $118,000 after purchasing an additional 110 shares during the period. Eqis Capital Management Inc. boosted its position in Enanta Pharmaceuticals by 0.6% during the second quarter. Eqis Capital Management Inc. now owns 31,565 shares of the biotechnology company’s stock worth $1,136,000 after purchasing an additional 173 shares during the period. SG Americas Securities LLC boosted its position in shares of Enanta Pharmaceuticals by 5.8% in the second quarter. SG Americas Securities LLC now owns 4,354 shares of the biotechnology company’s stock valued at $157,000 after acquiring an additional 237 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its position in shares of Enanta Pharmaceuticals by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 53,616 shares of the biotechnology company’s stock valued at $1,930,000 after acquiring an additional 304 shares during the period. Institutional investors own 66.04% of the company’s stock.

Enanta Pharmaceuticals (NASDAQ ENTA) traded up $0.24 on Monday, reaching $47.97. 129,900 shares of the company’s stock were exchanged, compared to its average volume of 192,381. Enanta Pharmaceuticals has a 52-week low of $25.92 and a 52-week high of $50.92.

WARNING: This piece of content was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/11/13/enanta-pharmaceuticals-inc-enta-given-average-recommendation-of-buy-by-brokerages.html.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply